Loading patent…
AssigneeNational Research Council of Canada
InventorsSergio P. ALPUCHE-LAZCANO, Matthew STUIBLE, Yves DUROCHER, Zalma Vanesa SANCHEZ MARTINEZ
Estimating the term…
Provided is an enveloped virus-like particle (eVLP) comprising a substantially full-length recombinant SARS-CoV-2 spike (S) protein. The eVLP may further comprise an additional recombinant SARS-CoV-2 S protein having a different sequence, another recombinant viral antigen, or a recombinant non-viral protein. The eVLP is derived from an animal cell, such as a CHO cell, expressing the recombinant SARS-CoV-2 spike protein. Also provided are methods of producing such eVLPs, compositions including such eVLPs, and methods and uses for the induction of an immune response against a SARS-CoV-2 spike protein and/or prevention of COVID-19 or SARS-CoV-2 infection, employing such eVLPs.
An enveloped virus-like particle (eVLP) derived from an animal host cell, wherein the eVLP comprises a substantially full-length recombinant SARS-CoV-2 spike protein.
The eVLP of any one of claims 15 to 19, wherein the additional recombinant protein comprises an influenza A antigen.
Dependencies are inferred from the claim text.